Stem Cell Stocks: A Complete List from “A” to “Z”
Biotech investing has become increasingly attractive, with stem cell research standing out as a sector ripe with innovation and potential. Stem cell technology, with its ability to revolutionize treatments for illnesses, reverse injuries, and beyond, has drawn significant attention from investors looking to capitalize on groundbreaking advancements. But with so many companies entering the field, it can be challenging to track the leading players and emerging opportunities.
In this comprehensive guide, we provide a list of stem cell stocks, categorized from A to Z, to help you navigate this dynamic market. Whether you’re a seasoned investor seeking diversification or a biotech enthusiast eager to support transformative science, this article will highlight all known stem cell stocks that are listed on the public markets. [Read more…]
RoslinCT and Ayrmid Pharma Enter Into a Strategic Partnership to Manufacture FDA Approved Cell Therapy Omisirge® (omidubicel-onlv)
Intent that RoslinCT is to perform technology transfer and commercial manufacture of Omisirge® at RoslinCT’s cell therapy manufacturing facility in Hopkinton, MA.
Omisirge® is a commercialized mismatched unrelated cell therapy derived from the youngest donor source and banked for ease of infusion for patients with hematological malignancies.
Cellino and Matricelf Collaborate to Scale iPSC-Derived Treatments for Spinal Cord Injury (SCI)
Cellino successfully manufactures and delivers autologous iPSC lines from four donors to Matricelf for groundbreaking neural tissue engineering.
Matricelf transformed Cellino-generated iPSCs into functional neural tissues with synchronized electrical activity.
CAMBRIDGE, Mass. – Cellino and Matricelf (TASE: MTLF) announced a collaboration to accelerate the global biomanufacturing of personalized spinal cord injury treatments using Cellino’s Nebula™ technology combined with Matricelf’s breakthrough regenerative approach. This collaboration combines Cellino’s automated iPSC manufacturing with Matricelf’s double autologous 3D differentiation process, paving the way for scalable, patient-specific regenerative therapies. [Read more…]
Cardiac Stem Cell Therapies for Heart Failure Treatment
Human life is dependent upon the heart’s ability to pump forcefully and frequently enough, but heart failure signs can disturb its normal function. Most humans cannot live more than four minutes without a heartbeat or continuous blood-flow. At that time, brain cells begin to die because they lack adequately oxygenated blood-flow.
The human adult body requires, on average, 5.0 liters of re-circulated blood per minute. In the cardiology field, this metric is called the “Cardiac Output,” which is calculated as “Stroke Volume (SV)” x “Heart Rate (HR).” Another key metric is a patient’s “Ejection-Fraction (EF %).” A patient’s EF tells a cardiologist and other physicians if his or her heart is functioning normally or “low normally.” It is a measurement of one’s heart contraction, with a normal EF range being 55-70%. [Read more…]
- « Previous Page
- 1
- …
- 61
- 62
- 63
- 64
- 65
- …
- 336
- Next Page »